A Prospective Evaluation of Spinal Cord Induced Muscle Stimulation (MuscleSCS) for the Treatment of Chronic Low Back Pain

NCT07215104 | Recruiting FDA Device

• 1 other identifier: MuscleSCS Study V2.0
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a prospective, multi-center study designed to compare the safety and efficacy of spinal cord induced muscle stimulation (MuscleSCS) for the treatment of chronic low back pain.

Conditions

Chronic Low Back Pain (CLBP)

Outcome Measures

Primary Outcomes (6)

• NRS

  Numerical Rating Scale for Pain

  Enrollment to End of Study (3mo Visit)

• ODI

  Oswestry Disability Index

  Enrollment to End of Study (3mo Visit)

• EQ5D-5L

  5 Dimension Health Related Quality of Life Questionnaire

  Enrollment to End of Study (3mo Visit)

• PDI

  Pain Disability Index

  Enrollment to End of Study (3mo Visit)

• PCS

  Pain Catastrophizing Scale

  Enrollment to End of Study (3mo Visit)

• PGIC

  Patient Global Impression of Change

  Enrollment to End of Study (3mo Visit)

Interventions

MuscleSCS DEVICE

The population for this study will include two specific groups of the same pain population. Group one is the Pre-existing SCS Group, these are pain patients with chronic back pain, and who have been implanted with an SCS system with a percutaneous lead or a paddle lead and BurstDRTM IPG for more than 6 month and having success with their BurstSCS stimulation (\>50% pain relief). Group two is the Trial SCS Group, these are pain patients with chronic back pain, and who have been determined to be candidates for trial and potential permanent SCS with a percutaneous lead or a paddle lead and BurstDRTM IPG.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with PSPS type 1 and 2
• Patients with predominant back pain
• Patient must be willing and able to provide written informed consent before any clinical investigation-related procedure
• Age ≥18 y
• Patients with SCS(BurstDR) stimulation in situ for more than 6 month and \>50% pain relief. Patients have to be satisfied with their existing SCS therapy and predominantly use a BurstDR stimulation program.
• (Only responders to that therapy should be included, not patients who have not responded to their therapy so far.) \[GROUP 1\]
• Low back pain baseline score of ≥6 on NRS before spinal cord stimulation therapy and a MCID (Minimal clinically important difference) of \>50% with SCS(BurstDRTM) trial stimulation. \[GROUP 2\]
• Willing and able to comply with the instructions for use, operate the study device, and comply with this clinical investigation plan

You may not qualify if:

• Pathology seen on imaging tests obtained within the past 12 month that is clearly identified and is likely the cause of the CLBP, that can be addressed with surgery
• Primary symptom of leg pain, or leg pain is greater than back pain
• Back pain is due to any of the following: vascular causes (eg, aortic aneurysm), spinal infection (eg, osteomyelitis), inflammation or damage to the spinal cord (eg, arachnoiditis or syringomyelia), tumor or spinal metastases
• Has widespread pain (eg, fibromyalgia) or pain in other area(s), not intended to be treated in this study (eg, neck pain, shoulder pain)
• Patient has used a morphine equivalent daily dose of \>50 MME in the last 30 days
• Patients with regular intake of systemic steroids (except inhaled steroids used to treat asthma)
• Imaging (MRI, CT, x-ray) findings within the last 12 mon that contraindicate lead placement
• Known allergic reaction to implanted materials
• Severe scoliotic deformity (\>11◦ in thoracic or lumbar spine)
• Patient has a history of or existing intrathecal drug pump
• Patient with other existing implantable electrical devices, i.e. pacemakers, bladder stimulators, etc.
• Patient has previous experience with neuromodulation devices, including a failed trial
• BMI \>40
• Patient is enrolled, or intends to participate, in another clinical drug and/or device study or registry that may interfere with the results of this study.
• Presence of other anatomic or comorbid conditions, or other medical, social, or psychologic conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results

Sponsors & Collaborators

• Saint Francis Hospital: lead
• Abbott Medical Devices: collaborator

Study Sites (1)

WVUM/Thomas Hospitals (Saint Francis Hospital) Spine and Nerve Center

Charleston, West Virginia, 25301, United States

RECRUITING

Study Officials

• Timothy R Deer, MD

  WVUM/Thomas Hospitals (Saint Francis Hospital) Spine and Nerve Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Amy Young, RN, BSN, DMPNA

CONTACT

304-347-6144; amelia.young3@wvumedicine.org

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: The population for this study will include two specific groups of the same pain population. Group one is the Pre-existing SCS Group, these are pain patients with chronic back pain, and who have been implanted with an SCS system with a percutaneous lead or a paddle lead and BurstDRTM IPG for more than 6 month and having success with their BurstSCS stimulation (\>50% pain relief). Group two is the Trial SCS Group, these are pain patients with chronic back pain, and who have been determined to be candidates for trial and potential permanent SCS with a percutaneous lead or a paddle lead and BurstDRTM IPG.

Study Record Dates

• First Submitted: October 8, 2025
• First Posted: October 10, 2025
• Study Start: October 7, 2025
• Primary Completion (Estimated): October 7, 2026
• Study Completion (Estimated): January 1, 2027
• Last Updated: October 10, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)